Navigation Links
Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function

SAN FRANCISCO, May 07, 2007 /PRNewswire/ -- Interim results from a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil) were presented at the American Transplant Congress. This and other Spare the Nephron (STN) trials in kidney and liver transplant recipients examine ways to prevent rejection without damaging kidneys.

As transplant patients are living longer, doctors are finding that older therapies such as steroids and calcineurin inhibitors (CNIs) can cause impairment of kidney function and damage to the blood vessels and filtering capacity of the kidneys.(1)(2) The STN trials are being conducted at more than 35 transplant centers in the United States and Canada and use CellCept and other immunosuppressants in combinations that reduce or eliminate the use of steroids and CNIs.

"Our goal for the Spare the Nephron trial in kidney transplant recipients is to determine the safest and most effective immunosuppressive therapy regimen that avoids the nephrotoxic effects of CNIs while preventing rejection," said Matthew Weir, M.D., professor and director of the division of nephrology at the University of Maryland School of Medicine. "The preliminary study results are very encouraging."

Dr. Weir reported that first-year results in kidney transplant recipients demonstrated that patients on CellCept and sirolimus maintenance therapy showed improvements in glomerular filtration rate (GFR) of their kidneys without increasing rejection rates.

A total of 208 of 305 kidney transplant patients completed 12 months of follow-up in this open-label, prospective, randomized, multicenter study. Patients initially treated with CellCept and a CNI were randomized to receive CellCept and sirolimus or to continue their current treatment regimen of CellCept and a CNI. Efficacy endpoints included the proportions of patients experiencing acute reject
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
2. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
3. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
4. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
5. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
6. Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data
7. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
8. Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron
9. Immediate Treatment of Early MS Patients with Betaferon Significantly Delayed Permanent Disability
10. First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
11. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
Post Your Comments:
(Date:12/1/2008)...d today announced the initiation of a Phase 1/2 cl... JAK2 inhibitor, in leading medical centers in Aus...ibrosis (CIMF). , , The trial is designed ...in patients with CIMF and is expected to enrol up ...l assess the safety profile and evaluate the pharm...
(Date:12/1/2008)...NB-0040 at Children,s Hospital, Health Sciences Ce...wswire/ -- Enobia Pharma, an emerging Canadian bio...ics for serious bone disorders, today announced th...m for hypophosphatasia was dosed. Enobia is invest...0040 for the treatment of this rare and often crip...
(Date:12/1/2008)... , ROCHESTER, Minn., Dec. 1 /PRNewswire-USNew...se of the drug therapy etanercept ineffective in t... of the liver caused by excessive consumption of a...the December issue of Gastroenterology ( http://... Additional audio and video resources, including e...
(Date:12/1/2008)...-FirstCall/ -- Following a,Request for Proposal i...sed,third generation smallpox vaccine, Public Wo...the Canadian Department of National Defence, has a...very of IMVAMUNE(R). , The Canadian authori...ntry,s bio-preparedness programme. , The co...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 1Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 2Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 3Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 4Human Genome Sciences to Sponsor Conference Call 2319 1Human Genome Sciences to Sponsor Conference Call 2319 2Tufts researchers update their food guide pyramid for older adults 8590 1Tufts researchers update their food guide pyramid for older adults 8590 2Tufts researchers update their food guide pyramid for older adults 8590 3Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 1Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 2Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 3Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 4
...URG, Germany, May 10th, 2007 - Antisense,Pharma, a...argeted,therapies for malignant tumors, today anno...12009 in high-grade glioma will be,presented at th...linical Oncology (ASCO), which will be held in Chi...he open-label, randomized dose-finding Phase,IIb-t...
...praisal Committee concludes that alteplase is clin... 14 May 2007 – A new clinical appraisal,publ...nical,Excellence (NICE) in the UK has recommended ... with acute ischaemic stroke, based on,its clinica...tive,care alone.1 Alteplase is marketed as Actilys...
Other Medicine Technology:2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 2Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 4Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 5
(Date:12/2/2008)... Trials of tasimelteon show it could aid shift wo...ESDAY, Dec. 2 (HealthDay News) -- The experimental...aused by jet lag or night shifts, according to the...e II study included 39 people randomly assigned to... mg of tasimelteon, or a placebo. They were monito...
(Date:12/2/2008)... ORLANDO, Fla., Dec. 2 MEDai, Inc...care solutions provider, has added a new module,t...ons. The new stand-alone,module monitors a popul...delines and alerts stakeholders when there has bee...e Risk Navigator Guidelines(TM) provides,real-tim...
(Date:12/2/2008)... -Survey Reveals Nearly Half Have Skipped Medical...., Dec. 2 A new survey ...urce Center (NWHRC) highlights another troubling a...have failed to seek health care for themselves or ...ate that many women say their health has gotten wo...
(Date:12/2/2008)... MALVERN, Pa., Dec. 2 Arlington M...ket intelligence for the pharmaceutical and diagno...Janssen Pharmaceuticals, Levaquin,is the preferre... general,medical-surgical hospitals in the United...lung, sinus, skin and urinary tract infections cau...
Breaking Medicine News(10 mins):Health News:Drug Effective for Temporary Sleep Disruptions 2Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:Rising Health Costs Prompt Women to Neglect Health 2Health News:Rising Health Costs Prompt Women to Neglect Health 3Health News:Rising Health Costs Prompt Women to Neglect Health 4Health News:Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States 2
... Holtgrave, PhD, an expert on HIV prevention at th... a targeted campaign of testing and counseling aim... more effective than the mass patient screening pr...rol and Prevention (CDC). Holtgraves study is the...
...issue of CHEST, reports that children receiving an...r risk for developing asthma by age 7 than those ...oubled in children receiving antibiotics for nonre...ldren who received multiple antibiotic courses and...
... the issue of Neurology, the scientific journal of...easily distressed and have more negative emotions ...ore easygoing people. In the study, those who mos...ch as depression and anxiety were 40 percent more ...
...es re-sat their examinations Monday after a cheati...lts, an official said Monday . Lawyers hired by th...hools (CGFNS) acted as observers at examination ce...vao. Labour Secretary Arturo Brion said the gradu...
Other Medicine News:Health News:Targeted HIV Testing An Effective Way to Screen HIV Patients 2Health News:Antibiotic Use in Infants may Lead to Asthma. 2Health News:Pessimists may Develop More Memory Problems 2Health News:Philippine Nurses Re-sit Scandal-tainted Exams 2
Cold light source single outlet.
Cold light source triple outlet.
Cold light source single outlet.
The 9100 is a truly affordable 100 Watt xenon light source providing accurate color and brightness. This xenon light source is ideal for surgery centers, evaluations or general office use.
Medicine Products: